DiaMedica Therapeutics Inc. (DMAC) Stock: Here’s What’s Happening


DiaMedica Therapeutics Inc. (DMAC) is working its way for to the bottom in the market today. The stock, one that is focused on the biotechnology space, is presently trading at $2.43 after tumbling -5.08% so far in today’s session. In terms of biotechnology stocks, there are quite a few factors that have the potential to lead to movement in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines surrounding DMAC:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-13-19 04:35PM DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
Aug-12-19 08:00AM DiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
Aug-08-19 04:00PM DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
Jun-21-19 07:18AM The Daily Biotech Pulse: ContraVir’s Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
Jun-20-19 07:25AM The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge

However, when making a decision with regard to investing, investors should look at much more than news, this is especially the case in the generally speculative biotechnology space. Here’s what’s happing when it comes to DiaMedica Therapeutics Inc..

Recent Movement Out of DMAC

While a single session decline, like what we’re seeing from DiaMedica Therapeutics Inc. may cause fear in some investors, that by itself should not be the reason for a decision to, or not to, buy a company’s stock. It is generally smart to take a look at trends experienced by the stock further out than a single trading session. In the case of DMAC, here are the trends that we’ve seen:

  • Weekly – In the past five trading sessions, DMAC has seen a price change in the amount of -23.10%.
  • Monthly – The performance from DiaMedica Therapeutics Inc. throughout the last 30 days has been -33.42%.
  • Past Three Months – Over the last 3 months, the stock has produced a return on investment that works out to -15.63%
  • Past 6 Months – Over the previous six months, we’ve seen a change that works out to -29.57% from the stock.
  • YTD – Since the the last trading session of last year DMAC has resulted in a ROI of -16.49%.
  • Full Year – Finally, in the past year, investors have seen movement that comes to -68.22% out of DMAC. Over this period, the stock has traded at a high of -75.70% and a low price of 9.95%.

Key Ratios

Digging into various key ratios having to do with a stock can provide prospective investors an understanding of just how risky and/or potentially profitable a pick may be. Here are a few of the most important ratios to consider when digging into DMAC.

Short Ratio – The short ratio is a tool that’s used by investors to measure the level of short interest. As the short ratio goes higher, it shows that more investors are expecting that the value of the stock is headed for declines. Throughout the sector, biotech stocks tend to carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the space. Nonetheless, in regard to DiaMedica Therapeutics Inc., it’s short ratio clocks in at 0.09.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure If a company is able to pay for its debts when they mature based on quick assets or current assets. In the biotech sector, several companies rely heavily on continued support from investors, the quick and current ratios can be damning. However, some gems in the biotechnology industry do have good quick and current ratios. As it relates to DMAC, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price of the stock. In this case, the book to share value ratio works out to 0.98.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re looking into a biotechnology stock, this is a very important ratio to consider. In the case of DMAC, the cash to share value works out to 0.

How Analysts Feel About DiaMedica Therapeutics Inc.

Although it’s rarely a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to consider their analysis in order to validate your own thoughts before making an investment decision in the biotech space. Below are the recent moves that we have seen from analysts when it comes to DMAC.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-30-19 Initiated Dougherty & Company Buy $8
Mar-05-19 Initiated Lake Street Buy $9

Big Money And DiaMedica Therapeutics Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in DMAC, here’s what we’re seeing:

Institutions own 13.72% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 8.37% percent of DMAC shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 11.96M shares of DiaMedica Therapeutics Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, DMAC has a float of 9.09M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to DMAC, the short percent of the float is 0.12%.

Financial Results And Expectations

What have ween seen from DMAC in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts expect that DiaMedica Therapeutics Inc. will report EPS in the amount of 0, with 0 to be announced in the earnings announcement for the current quarter. Although this information isn’t based on earnings, since we’re chatting about Wall St. analysts, the stock is currently rated a 0 on a scale from 1 to 5 on which 1 is the worst possible Wall St. analyst rating and 5 is the best.
  • 5-Year Sales – In the past 5 years, DiaMedica Therapeutics Inc. has announced a movement in sales volume that comes to a total of 0. EPS through the last 5 years have experienced movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is generally explained in the human world, the company has seen a earnings change by 0. DiaMedica Therapeutics Inc. has also experienced movement in regard to revenue that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I’m incredibly dependent on humans. You may not consider this when reading my articles, but it was a human! While, my creators enabled me to learn, it is much easier to do so through the receipt of feedback from human beings. At the bottom of this content, you will see a comment section. If you’d like for me consider other data, evolve the way I write something, look at data from an alternative angle, or just about anything else, I’d love to know. To let me in on your thoughts leave a comment below. I will read your comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here